Sarawak sees 700-800 new kidney failure cases annually, 4,800 now on dialysis, says SGH nephrologist
KUCHING (May 11): Sarawak records between 700 and 800 new cases of kidney failure annually, with approximately 4,800 patients currently undergoing dialysis.
This alarming figure was revealed by Sarawak General Hospital (HUS) consultant nephrologist Dr Clare Tan Hui Hong during the launch of World Kidney Day 2025 at a shopping mall here today.
'Every year, we have about 700 to 800 new patients diagnosed with kidney failure who need to start dialysis. In total, we currently have around 4,800 patients on dialysis in Sarawak,' she told reporters after officiating the launch.
Dr Tan said the increasing number of kidney failure cases is concerning, emphasising the urgent need for preventive measures and greater public awareness.
'Dialysis centres are expanding. There are about 25 government-run dialysis facilities across Sarawak, with a new one set to open in Selangau Health Clinic by the end of the year. We also have around 12 charity-run centres, and more are in the pipeline,' she said.
Despite the growing number of dialysis centres, Dr Tan stressed that prevention remains far more critical than treatment.
'More than just focusing on dialysis, we must address the root issue — prevention. Raising awareness about kidney health is essential to slowing down the number of people progressing to kidney failure.'
She also cited national health survey data showing a worrying trend: the prevalence of chronic kidney disease (CKD) in Malaysia increased from 9.07 per cent in 2011 to 15.5 per cent in 2018 — rising from roughly one in 11 persons to one in six or seven.
Although no new nationwide surveys have been conducted since 2018, Dr Tan expressed hope that initiatives like World Kidney Day campaigns could reverse the upward trend.
This year's World Kidney Day carries the theme 'Detect Early, Protect Kidney Health', emphasising the importance of early detection and lifestyle interventions in reducing CKD cases.
'Let us work together to fight the epidemic of chronic kidney disease and to stop this epidemic,' Dr Tan urged.
Also present at the event were Kelab Rotary Kuching president Charlie Ong, COR Holder of NKF Kota Samarahan Dr Nurizaidah Ishak, and NKF Kota Samarahan regional unit coordinator Nur Ezzatul Sahadah Jelani. dialysis Dr Clare Tan kidney failure lead
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Star
4 days ago
- The Star
Game-changing treatment for advanced prostate cancer
Prostate cancer is the third most common cancer among Malaysian men, with cases rising steadily since 2012. While it trails behind colorectal and lung cancer, it is still a significant concern. What's more worrying is that many cases are detected late. Early-stage prostate cancer is highly treatable, but late-stage cases are far more difficult to manage. What is prostate cancer? The disease begins when cells in the prostate – a small, walnut-sized gland below the bladder – start to grow uncontrollably. In its early stages, prostate cancer often causes no symptoms. But as the tumour grows, it can press against the urethra – the tube that carries urine – leading to changes in urination. Left untreated, the cancer can spread to nearby tissues, lymph nodes, or even the bones, making it more difficult to treat and manage. Yet, many men overlook the early signs. However, symptoms such as difficulty urinating, weak flow, or frequent trips to the bathroom at night may be early warning signs of prostate cancer. Sunway University consultant urologist and urologic oncologist Professor Dr Tan Guan Hee explains that these symptoms often go unnoticed or are mistaken for benign prostate conditions such as benign prostatic hyperplasia. 'Many men assume it's just part of getting older and delay seeing a doctor,' he says. 'Unfortunately, this means prostate cancer is often diagnosed at a later stage, when it's more difficult to treat.' As Malaysia's population continues to age, the number of prostate-related issues is expected to rise in tandem. Despite this, there is a general lack of awareness of the problem, minimal symptoms in early stages, and a cultural reluctance to seek help for intimate health issues. When prostate cancer is detected early, treatment options such as surgery or radiotherapy are often effective and potentially curative. However, late-stage prostate cancer, which may have already spread to bones or lymph nodes (metastasised), requires more advanced interventions. This is where radioligand therapy (RLT) offers new hope. Overcoming stigma One significant and often overlooked challenge in managing prostate cancer is cultural reluctance. Many patients delay seeking care due to embarrassment or denial, particularly Asian men, who may be more reserved about discussing health issues. Doctors often find that families bring in patients who have ignored symptoms for years. Prof Tan says: 'Addressing this cultural barrier requires greater public awareness, normalising conversations around men's health, and encouraging routine screening and early intervention.' Beyond individual awareness, family involvement plays a critical role in detecting early symptoms of prostate cancer and preventing critical outcomes. 'If children notice their father is frequently going to the toilet, they might realise something is amiss and encourage him to seek medical help,' he suggests. Treatment for prostate cancer depends on what stage the tumour is at. — Photos: Canva Precision treatment According to consultant clinical oncologist Dr Nik Muhd Aslan Abdullah, treatment for prostate cancer has come a long way since the 1990s. While surgery, radiotherapy and hormonal therapy remain standard options, recent advances in precision medicine have led to more targeted, effective treatments. Choosing the most appropriate treatment depends on several factors, including: > The stage of the cancer > The patient's age > Personal preferences > Underlying health conditions that may make certain treatments, such as surgery, unsuitable. 'In the past, our precision treatment options were quite limited. 'But today, we are guided by clearer staging and more accurate tools,' he says. Dr Nik outlines the four key stages that influence treatment strategy: > Stage 1: The tumour is confined to the prostate and involves no more than half of the gland. > Stage 2: The tumour remains within the prostate but is more advanced. > Stage 3: The tumour has grown beyond the prostate and may have reached nearby structures such as the seminal vesicles, rectum or bladder. > Stage 4: The cancer has spread to the lymph nodes or distant parts of the body, such as the bones. 'To determine the stage, we typically rely on three approaches: physical examination, blood tests, particularly for prostate-specific antigen (PSA), and imaging. 'Conventional imaging includes computed tomography (CT) scans, magnetic resonance imaging (MRI), and bone scans,' he explains. However, these methods have their limitations. Dr Nik adds: 'They may miss early tumours or small areas of spread, and while blood tests are helpful, they cannot show the precise location of the cancer.' Sharper detection with PSMA PET-CT A key development is PSMA PET-CT imaging – a powerful diagnostic tool that combines positron emission tomography (PET) with CT to detect prostate-specific membrane antigen (PSMA), a protein found on most prostate cancer cells. 'About 80% of prostate cancer cells have a protein called PSMA on their surface,' explains Sunway University consultant nuclear medicine physician Associate Prof Dr Tan Teik Hin. 'We use this to both detect and treat cancer. The approach is simple: we treat what we see, and we see what we treat.' PSMA PET-CT works like a GPS for cancer cells. The CT maps the body's structure, while the PET scan lights up areas where PSMA-positive cancer cells are present. It can detect tumours as small as 0.3cm, far smaller than what conventional scans typically reveal. In an April 2020 ProPSMA study published in The Lancet , researchers found that this method was 27% more accurate than traditional imaging, often leading to significant changes in treatment planning. What is radioligand therapy or RLT? Once PSMA-positive cancer cells are identified, patients may be eligible for RLT. This treatment uses a radioactive compound that binds specifically to PSMA on cancer cells, delivering a precise dose of radiation directly to the tumour while sparing surrounding healthy tissue. Assoc Prof Teik Hin says: 'It's like sending a guided missile to destroy only the cancer cells. 'RLT is not entirely new. A similar concept – using radioactive iodine to treat thyroid cancer – has been in use for over 80 years. 'What's new is applying the same principle to prostate cancer using more advanced, highly specific radiotracers.' After treatment, a follow-up scan (SPECT-CT, a hybrid imaging technique that combines Single Photon Emission Computed Tomography and CT) is conducted to confirm that the radioligand successfully reached and treated the target. From left: Assoc Prof Teik Hin, Prof Tan and Dr Nik were the three medical professionals who led the roundtable discussion on RLT. — Handout Fewer side effects One of the greatest advantages of RLT is its specificity. Because the therapy targets only cancerous cells, it causes fewer side effects compared to systemic treatments like chemotherapy or hormonal therapy. Most patients tolerate it well, with mild side effects such as dry mouth, fatigue or nausea. More importantly, studies show that RLT can help delay disease progression, reduce symptoms like pain, and improve quality of life, especially for men with advanced or castration-resistant prostate cancer. While RLT is currently used mainly for patients with stage 4 prostate cancer who no longer respond to other treatments, ongoing clinical trials are exploring its use at earlier stages. PSMA PET-CT is also being studied for its ability to guide biopsies and detect cancer even before a formal diagnosis is made. 'Compared to systemic hormone therapy, which affects the entire body and can cause fatigue and mood changes, RLT offers a more targeted approach with fewer disruptions to daily life. 'We see a marked improvement in quality of life, and patients report less pain, more energy, and better sleep after the therapy,' says Assoc Prof Teik Hin. The treatment is available at government facilities such as the National Cancer Institute (IKN) in Putrajaya and Hospital Kuala Lumpur, as well as at several private hospitals. The cost of RLT varies depending on the hospital, the number of treatment cycles, and individual response to the treatment. As there is no fixed price, patients are encouraged to consult their medical team to discuss affordability and explore available financial support options. The three experts were discussing 'Size Matters in Prostate Cancer: Experts Highlight Advances to Close Critical Gaps in Care,' in a media roundtable held recently at a private hospital in Petaling Jaya, Selangor.
New Straits Times
24-07-2025
- New Straits Times
Size does matter
FOR men, an enlarged prostate can be one of the earliest signs that something is amiss. However, it and other symptoms, such as difficulty urinating, are often dismissed as normal signs of ageing. In Malaysia, prostate cancer is the third most common cancer among men and as Malaysia shifts towards an ageing nation, more men will be at risk. Yet, close to three-quarters of cases are diagnosed in advanced stages, where complications are more severe, treatment options limited and survival rates significantly reduced. Prostate cancer is insidious, often silent and frequently ignored until it's too late, says Sunway Medical Centre consultant urologist Professor Dr Tan Guan Hee. "Yes, size usually matters. When the prostate is enlarged or urinary symptoms appear, that should trigger a check, not a shrug," he adds. "The assumption that it's just ageing can delay diagnosis and lead to poorer outcomes." Dr Tan says the five-year relative survival rate for stage 4 prostate cancer is only 43.2 per cent, according to the Malaysian Study on Cancer Survival — a stark reminder of the price of late diagnosis. Critical gaps remain in how Malaysian men approach prostate health, including delayed symptom recognition, where urinary changes or an enlarged prostate are often ignored instead of investigated. Many cases are only detected when the disease is advanced, potentially due to the limitations of conventional imaging methods which can miss small or early metastases. Limited awareness of advanced diagnostic and treatment options is also a factor. Addressing these gaps is key, particularly as Malaysia's population continues to age. "When patients are diagnosed early, their chances of survival and quality of life significantly improve." The challenge is ensuring men seek medical help before the disease becomes aggressive and spreads to the bone, says Sunway Medical Centre consultant clinical oncologist Dr Nik Muhd Aslan Abdullah. A promising innovation in terms of treatment, meanwhile, is theranostics — a dual approach that combines targeted imaging with targeted therapy. The use of theranostics, along with greater awareness and screening efforts, could help reverse current trends by detecting what conventional methods might miss and improve quality and duration of life after treatment, even among those with advanced or metastatic cancer.
Free Malaysia Today
23-07-2025
- Free Malaysia Today
2,293 patients on wait list for cardiothoracic surgery, some up to 7 months
Health minister Dzulkefly Ahmad said patients at government hospitals faced long wait times to undergo procedures such as coronary artery bypass graft or surgery to remove kidney stones. (Bernama pic) PETALING JAYA : A total of 2,293 patients are on a waiting list to undergo cardiothoracic surgeries in government hospitals, with some of them facing an average wait time of seven months, says health minister Dzulkefly Ahmad. In a written parliamentary reply, Dzulkefly said patients waiting to undergo procedures such as coronary artery bypass graft must wait about seven months on average. Meanwhile, there were 603 elective cases of paediatric cardiothoracic surgery, with the patients needing to wait an average of 21 months. 'This service is available in seven government hospitals that provide cardiothoracic surgeries. 'Paediatric cardiothoracic surgeries are in the meantime conducted by adult cardiothoracic specialists or referred to the National Heart Institute (IJN) because paediatric cardiothoracic surgeons are still being trained,' he said. Dzulkefly said 2,661 patients were waiting to undergo procedures to remove kidney stones, with each one expected to wait 11 months. He said the procedure was only provided by 13 public hospitals with resident urology surgeons. Another 9,233 patients are waiting to undergo cataract surgeries, with a waiting period of about three months. He said 56 government hospitals provided this operation. To reduce the wait time for surgical procedures, Dzulkefly said the ministry had placed more surgical specialists in more hospitals without a resident specialist. It is also working to reduce wait times through public-private partnerships.
